No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia

https://doi.org/10.1016/j.schres.2013.02.001Get rights and content

Abstract

Schizophrenia has been associated with low glutathione (GSH), one of the most important substrates for natural defense against oxidative stress. This abnormality is often attributed to genetic or other pathological causes. However, low GSH in schizophrenia could also be due to insufficient antioxidant consumption or other exogenous factors. We evaluated GSH in relation to diet, smoking, and medication status in schizophrenia patients. We recruited 54 participants (29 schizophrenia patients and 25 normal controls). The Antioxidant Dietary Source Questions was used to estimate the total antioxidant capacity (TAC) from participants' diet. GSH and the oxidized form of glutathione (GSSG) were assayed. We found that GSH was significantly lower (p < 0.001) while %GSSG was 2 to 5 fold higher (p = 0.023) in patients compared with controls. No evidence for lower TAC dietary intake was found in schizophrenia patients compared with controls; rather nominally higher TAC level was found in the patients diet (p = 0.02). Analysis of consumption of individual food categories also failed to find evidence of reduced dietary antioxidant intake in schizophrenia patients. Smoking and medications did not significantly predict the GSH deficit either. However, there was a significant smoking by diagnosis interaction on GSH (p = 0.026) such that smoking was associated with higher GSH level in controls while smoking in patients was not associated with this effect. Schizophrenia patients may have an impaired upregulation of GSH synthesis that normally occurs due to smoking-induced antioxidative response. Lower GSH was independently present in patients on clozapine (p = 0.005) and patients on other antipsychotics (p < 0.001) compared with controls. In conclusion, none of the exogenous sources played a major role in explaining abnormalities in the glutathione pathway in patients. The state of abnormal glutathione redox may therefore be a part of schizophrenia pathophysiology.

Introduction

Schizophrenia has been associated with increased oxidative stress (Do et al., 2009, Kano et al., 2012). In aerobic cells, reactive oxygen species (ROS) and free radicals are byproducts of oxidative metabolism. The defense against oxidative stress is complex, involving multiple enzymes and antioxidant compounds. One of the major mechanisms for sequestration of ROS and free radicals is through the glutathione pathway where the reduced form of glutathione (monomeric glutathione or GSH) is converted to its oxidized form (glutathione disulfide or GSSG). Glutathione is present mainly (~ 99%) in GSH form in the body (Lenton et al., 1999). Although there are multiple defense systems and several of them have shown to be abnormal in schizophrenia, low GSH concentration is perhaps among the most consistently reported in schizophrenia. Low GSH has been found in post-mortem brain samples (Yao et al., 2006, Gawryluk et al., 2011) and in-vivo magnetic resonance spectroscopy studies (Do et al., 2000, Wood et al., 2009). GSH levels were decreased in the blood of antipsychotics-free and antipsychotics-treated patients (Raffa et al., 2009) and in cerebrospinal fluid of drug-naive patients (Do et al., 2000) suggesting that it is not secondary to antipsychotics. Taken together, low GSH level in schizophrenia provides a good index of an abnormal redox state associated with this illness, which is relatively consistently observed and not attributed solely to treatment with antipsychotics. Administration of the glutathione precursor n-acetylcysteine (NAC) improved clinical symptoms in patients (Berk et al., 2008), further supporting the association of oxidative stress with schizophrenia. However, it is unclear whether the mechanism that produces such effects is a direct result of pathophysiology associated with schizophrenia, an indirect result of other related pathology, or arising from sources outside the primary disease process that may differ between patients and controls. Hence, we examined the potential role of three exogenous factors in mediating oxidative stress, as indexed by abnormal GSH and GSSG levels, in schizophrenia: diet, smoking and antipsychotics.

First, diet is an important source of variance in oxidative stress in the general population (Jenkinson et al., 1999, Watson et al., 2005). We assessed whether there is a deficit in intake of antioxidants in food in schizophrenia, as dietary antioxidant contents provide the substrate and also regulate enzymes in the redox pathways (Bagchi et al., 1997, Huber et al., 2002). One prior study found no evidence of reduced antioxidant intake in schizophrenia (Strassnig et al., 2005). Another study showed that lower plasma antioxidant levels were not correlated with body mass (Reddy et al., 2003). However, to date no study has assessed whether dietary antioxidant intake affects the reported glutathione deficit in schizophrenia.

Second, smoking can contribute to oxidative stress by increasing lipid peroxidation (Solak et al., 2005). However, smoking also induces a potent antioxidant response and increases systemic production of glutathione (Gould et al., 2011). One study found increases in antioxidant enzymes in schizophrenic patients who smoke (Zhang et al., 2007). More data are needed to clarify if smoking contributes to the decreased glutathione in schizophrenia.

Third, the oxidative profile of antipsychotics remains unclear; some studies show antioxidant properties (Parikh et al., 2003, Miljevic et al., 2010, Stojković et al., 2012, Zhang et al., 2012) or improvement of peripheral glutathione and antioxidant enzymes by antipsychotics (Raffa et al., 2009, Zhang et al., 2012). On the other hand, patients on clozapine have shown higher superoxide dismutase and lower glutathione peroxidase, which was interpreted as secondary to increased oxidative stress by clozapine (Miljevic et al., 2010). Hence, we tested if clozapine versus non-clozapine antipsychotics were correlated with glutathione abnormalities in schizophrenia.

Section snippets

Participants

We recruited 54 participants (age range 18–62 years): 29 medicated patients and 25 normal controls, frequency-matched on age, gender and smoking status (Table 1). Patients were recruited from outpatient clinics of Maryland Psychiatric Research Center and neighboring community clinics. Controls were recruited using local media advertisements. Exclusion criteria included major medical and neurological illnesses, history of head injury with cognitive sequelae, mental retardation, substance

GSH and %GSSG levels

Fasting whole blood GSH levels were significantly lower in patients compared with controls (p < 0.001) (Fig. 1A). Fasting GSSG levels were significantly higher in patients vs. controls: patients showed over 5-fold higher in %GSSG compared with controls (p = 0.023) (Fig. 1B). %GSSG in patients also showed large variance: three patients had %GSSG > 50%, largely because they had GSH levels close to zero. The difference remained significant (p = 0.027) even upon removal of these extreme cases: patients

Discussion

This study tested the hypothesis that dietary antioxidant intake, smoking, and antipsychotic medication contribute to abnormal GSH and GSSG levels in schizophrenia. We found no evidence to support the hypothesis that these factors are the primary sources for the abnormal glutathione redox state in patients (Table 2).

Smoking is highly prevalent in schizophrenia (Cooper et al., 2012) although its potential role in the oxidative stress abnormalities in schizophrenia remains unclear. Interestingly,

Role of funding source

Support was received from National Institutes of Health grants R01MH085646, R01DA027680, and R21DA033817.

Contributors

Elliot Hong and Alejandro Ballesteros designed the study. Ann Summerfelt, Pan Jiang and Alejandro Ballesteros collected the data. Elliot Hong and Alejandro Ballesteros managed literature searches and data analyses, and wrote the first draft of the manuscript. All authors contributed to interpretation of results, participated in critical revision of manuscript drafts and approved the final version.

Conflict of interest

All authors report no conflict of interests.

Acknowledgment

There are no further acknowledgements.

References (45)

  • V. Parikh et al.

    Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain

    J. Psychiatr. Res.

    (2003)
  • M. Raffa et al.

    Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients

    Prog. Neuropsychopharmacol. Biol. Psychiatry

    (2009)
  • P.K. Ranjekar et al.

    Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients

    Psychiatry Res.

    (2003)
  • R. Reddy et al.

    Reduced plasma antioxidants in first-episode patients with schizophrenia

    Schizophr. Res.

    (2003)
  • A. Rietveld et al.

    Antioxidant effects of tea: evidence from human clinical trials

    J. Nutr.

    (2003)
  • T. Stojković et al.

    Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain

    Prog. Neuropsychopharmacol. Biol. Psychiatry

    (2012)
  • M. Strassnig et al.

    Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia

    Schizophr. Res.

    (2005)
  • F. Tietze

    Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues

    Anal. Biochem.

    (1969)
  • S.J. Wood et al.

    Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation

    Neurobiol. Dis.

    (2009)
  • X.Y. Zhang et al.

    Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia

    Neuropharmacology

    (2012)
  • D. Bagchi et al.

    Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro

    Res. Commun. Mol. Pathol. Pharmacol.

    (1997)
  • M.H. Carlsen et al.

    The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide

    Nutr. J.

    (2010)
  • Cited by (0)

    View full text